Gleevec (Imatinib) for Desmoid Tumor

Overview
Gleevec, approved by the U.S. Food and Drug Administration (FDA), is primarily indicated for the treatment of chronic myeloid leukemia (CML) and other specific types of cancer. It’s sometimes prescribed off-label for treating desmoid tumors. Gleevec is also known by its drug name, Imatinib​​​​.

Gleevec works by inhibiting specific tyrosine kinases, which are proteins involved in the signaling pathways that regulate cell growth and division. By blocking these proteins, Gleevec can help slow down or stop the growth of cancer cells.

How do I take it?
Gleevec is administered orally, with the dosage and frequency depending on the specific condition being treated. According to the prescribing information, it should be taken with a meal and large glass of water. It is crucial to follow the health care provider's instructions precisely regarding how to take this medication.

Side effects
Common side effects of Gleevec include edema (fluid retention), nausea, vomiting, stomach pain, diarrhea, joint or muscle pain, skin rash, and feeling tired. 

Rare but serious side effects include severe edema; cytopenias (reduced levels of blood cells); severe congestive heart failure and left ventricular dysfunction; life-threatening liver damage; bleeding incidents; gastrointestinal perforation (tearing); cardiogenic shock and left ventricular dysfunction; severe skin reactions; hypothyroidism (underactive thyroid); potential harm to the fetus in pregnant people; slowed growth in children; and renal (kidney) toxicity.

For more information about this treatment, visit:

Label: Gleevec — Imatinib Mesylate Tablet — DailyMed

Desmoid Tumor: Types of Treatment — Cancer.Net